Journey Medical (DERM) EBIT (2020 - 2026)

Journey Medical (DERM) has reported EBIT for 7 consecutive years, with $456000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 115.86% year-over-year to $456000.0; the trailing twelve-month figure through Jun 2026 stood at -$3.0 million (up 56.15% YoY), and the FY2025 full-year result was -$8.2 million, up 40.25% from the prior year.
• EBIT rose to $456000.0 in Q2 2026 per DERM's latest filing, from -$1.5 million in the prior quarter.
• Across five years, EBIT topped out at $17.2 million in Q3 2023 and bottomed at -$10.1 million in Q1 2024.
• Historically, EBIT has averaged -$2.9 million across 5 years, with a median of -$2.9 million in 2024.
• The widest YoY moves for EBIT: up 281.68% in 2023, down 976.69% in 2023.
• Over 5 years, EBIT stood at -$10.0 million in 2022, then jumped by 78.95% to -$2.1 million in 2023, then soared by 206.18% to $2.2 million in 2024, then plunged by 119.83% to -$443000.0 in 2025, then surged by 202.93% to $456000.0 in 2026.
• According to Business Quant data, EBIT over the past three periods registered $456000.0, -$1.5 million, and -$443000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.